API | filgotinib

filgotinib Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV. ^Wikipedia

Chemistry

SMILES: O=C(Nc1nc2cccc(c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C5CC5
InChIKey: RIJLVEAXPNLDTC-UHFFFAOYSA-N
Mol. Mass: 425.51
ALogP: 1.98 Partition coefficient
ChEMBL Molecule:
filgotinib

More Chemistry

Pharmacology

Mechanism of Action:
- Tyrosine-protein kinase JAK1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

filgotinib | g-146034 | glpg0634 | glpg-0634

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (16)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (16)

Arthritis, Psoriatic (Phase 3)

Arthritis, Rheumatoid (Phase 4)

Axial Spondyloarthritis (Phase 2)

Biomarkers (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Healthy Volunteers (Phase 1)

Inflammatory Bowel Diseases (Phase 2)

Interleukin-6 (Phase 3)

Janus Kinase Inhibitors (Phase 3)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 1)

Lupus Erythematosus, Cutaneous (Phase 2)

Spondylitis, Ankylosing (Phase 3)

Ultrasonography (Phase 3)

Uveitis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 43
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue